Neurocrine Biosciences
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults
September 12, 2023Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial
Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …
FDA approves first endometriosis pain management drug in a decade
July 25, 2018Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma
The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …
Neurocrine’s Ingrezza flops in Tourette’s for second time
May 25, 2017Research and Development, Sales and Marketing Neurocrine Biosciences, tourette's
Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …
FDA approves first and only tardive dyskinesia treatment
April 12, 2017Research and Development, Sales and Marketing FDA, Neurocrine Biosciences, tardive dyskinesia
US patients suffering with tardive dyskinesia (TD) will see access to the first approved treatment in the country with the …
